XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.1
Collaboration and License Agreements - Janssen Pharmaceuticals, Inc - Additional Information (Detail)
3 Months Ended 6 Months Ended
Oct. 03, 2018
USD ($)
Target
Obligation
Mar. 31, 2021
USD ($)
Mar. 31, 2020
USD ($)
Mar. 31, 2021
USD ($)
Mar. 31, 2020
USD ($)
Sep. 30, 2020
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Proceeds from the issuance of common stock         $ 250,479,000  
Revenues   $ 32,811,000 $ 23,529,000 $ 54,113,000 52,983,000  
Contract liabilities, current deferred revenue   144,879,000   144,879,000   $ 19,291,000
Collaboration and License agreements            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Initial transaction price $ 252,700,000          
JJDC | Common Stock Purchase Agreement            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Agreement date Oct. 03, 2018          
Proceeds from the issuance of common stock $ 75,000,000.0          
Janssen and JJDC | Collaboration and License agreements            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Cash received as due under collaboration agreement $ 175,000,000.0          
Janssen | License Agreement            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Agreement date Oct. 03, 2018          
Janssen | License Agreement | Maximum            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Development, regulatory and sales milestones payments $ 1,600,000,000          
Janssen | Research Collaboration and Option Agreement            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Agreement date Oct. 03, 2018          
Number of additional targets for development, regulatory and sales milestone payments | Target 3          
Janssen | Collaboration Agreement | Maximum            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Development, regulatory and sales milestones payments $ 1,900,000,000          
Janssen | JNJ-3989 (ARO-HBV) Agreement            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Milestone payment $ 25,000,000.0 25,000,000.0   25,000,000.0    
Number of distinct performance obligations | Obligation 1          
Revenues   7,500,000 22,200,000 20,200,000 50,900,000  
Contract assets   600,000   600,000    
Contract liabilities, current deferred revenue   0   0    
Janssen | ARO-JNJ1            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Revenues   100,000 $ 1,400,000 300,000 $ 2,100,000  
Contract assets   300,000   300,000    
Contract liabilities, current deferred revenue   $ 0   $ 0